Brief: Karyopharm Therapeutics Provides Endometrial Cancer Program Update
03/12/2024 12:04
Dec 3 (Reuters) - Karyopharm Therapeutics KPTI.O :
* KARYOPHARM THERAPEUTICS PROVIDES ENDOMETRIAL CANCER
PROGRAM
UPDATE
* KARYOPHARM: HAS UPCOMING MEETING WITH U.S. FDA REGARDING
TREATMENT LANDSCAPE IN ENDOMETRIAL CANCER, IMPLICATIONS ON PHASE
3 XPORT-EC-042 TRIAL
* KARYOPHARM: INTENDS TO PROVIDE AN UPDATE ON ITS
ENDOMETRIAL
CANCER PROGRAM AS SOON AS PRACTICAL FOLLOWING DISCUSSION WITH
FDA
Source text: ID:nPnN8Tmba
Further company coverage: KPTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview